← Back
Data updated: Jun 28, 2026
PROVEPHARM SAS
Specialty Pharmaceuticals
PROVEPHARM SAS is a specialty pharmaceutical company with 3 FDA-approved products.
1946
Since
3
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
3 Small Molecules
PROVEPHARM SAS's Key Drugs
PROVEPHARM SAS's core commercial portfolio centers on BLUDIGO, PROVAYBLUE — its most strategically important drugs approved in the last 15 years.
PROVEPHARM SAS's Recent FDA Approvals
New NDA/BLA approvals for PROVEPHARM SAS over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
PROVEPHARM SAS's Therapeutic Areas
Disease areas where PROVEPHARM SAS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
PROVEPHARM SAS Pipeline Snapshot
Active clinical trials for PROVEPHARM SAS across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BLUDIGO leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (2)
Discontinued (0)
Company Info
- First Approval
- 1946-05-06
- Latest
- 2026-03-18
- Applications
- 3